ARRDC4

Across TCGA pan-cancer cohorts, ARRDC4 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ARRDC4 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ARRDC4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARRDC4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, KIRP, and STAD are the cancer types where ARRDC4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.153	0.720	<.001	45	view →
KIRP	OS	Median	All	0.106	0.692	<.001	30	view →
STAD	OS	Median	All	0.224	0.729	.007	15	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	All	0.505	0.788	.040	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
HNSC	OS	Median	All	0.183	0.660	.040	3	view →
UCEC	OS	Median	II,III,IV	1.000	0.325	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ARRDC4–BLCA (OS)

Open the BLCA breakdown →